(S)-( )-Ibuprofen

SKU: orb1224869

Description

An enantiomer of Ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form; also inhibits activation of NF-κB more effectively than (R)-ibuprofen (IC50=62 and 122 uM, respectively).(In Vitro):(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent.(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis.(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 μM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1.(S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation.(S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC50 of 61.7 μM.(In Vivo):(S)-(+)-Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model.

Key Properties

• CAS Number: 51146-56-6
• MW: 206.2808
• Purity: >98% (HPLC)
• Formula: C₁₃H₁₈O₂
• SMILES: C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O
• Target: COX
• Solubility: H2O: 1 mg/mL (Need ultrasonic and warming); DMSO: < 0.1 mg/mL

Bioactivity

• In Vivo:
  (S)-(+)-Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model. Animal model: NMRI (nu/nu) male mice (6-8 week old) injected with HCA-7 and HCT-15 cells. Dosage: 15 mg/kg/day. Administration: Intraperitoneal injection; five days a week; for 4 weeks. Result: Inhibited tumor growth of HCA-7 and HCT-15 xenografts in mice.
• In Vitro:
  (S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent. (S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis. (S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 μM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1. (S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation. (S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC50 of 61.7 μM. Cell Proliferation Assay Cell line: HCT-15 and HCA-7 cells. Concentration: 0 μM, 200 μM, 400 μM, 600 μM, 700 μM, 800 μM, 900 μM, and 1000 μM. Incubation time: 8 days. Result: Reduced concentration dependently cell survival in both cell lines to a similar extent. Cell Cycle Analysis Cell line: HCT-15 and HCA-7 cells. Concentration: 0 μM, 200 μM, 400 μM, 600 μM, 800 μM, 900 μM, and 1000 μM. Incubation time: 24 hours (HCT-15) or 20 hours (HCA-7). Result: Caused a G0/G1 phase block. Apoptosis Analysis Cell line: HCT-15 and HCA-7 cells. Concentration: 0 μM, 200 μM, 400 μM, 600 μM, 800 μM, 900 μM, and 1000 μM. Incubation time: 72 hours. Result: Induced cell apoptosis. Western blot analysis. Cell line: HCT-15 and HCA-7 cells. Concentration: 900 μM. Incubation time: 4 hours, 8 hours, 16 hours, 24 hours, 32 hours, 48 hours and 72 hours. Result: Decreased levels of Cyclin D1 protein.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

S)-Ibuprofen

Quick Database Links

Gene Symbol

COX